Furthermore, CD52 expression was identified on the vast majority of ovarian tumor-associated Tie2+ monocytes, independent of their relationship to VLC, suggesting Alemtuzumab can target the majority of Tie2+ monocytes. Here, TEK is linked to ovarian neoplasm.